Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table]
Schedule of Restructuring and Related Costs [Table]
Income Statement Location [Axis]
Income Statement Location [Axis]
Income Statement Location [Domain]
Income Statement Location [Domain]
Cost of sales [Member]
Cost of Sales [Member]
Research and development [Member]
Research and Development Expense [Member]
Selling, general and administrative [Member]
Selling, General and Administrative Expenses [Member]
Other [Member]
Other Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Cost and Reserve [Line Items]
Separation Costs
Separation Costs
Amount of expenses for special or contractual termination benefits provided to current employees voluntarily or involuntarily terminated under an ongoing benefit arrangement or one-time termination benefits plan associated exit or disposal activities pursuant to an authorized plan.
Asset Impairments
Asset Impairment Charges
Accelerated Depreciation
Restructuring and Related Cost, Accelerated Depreciation
Other
Other Restructuring Costs
Total
Restructuring Costs and Asset Impairment Charges
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table]
Schedule of Finite-Lived Intangible Assets [Table]
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Developed Product Technology Rights [Member]
Developed Technology Rights [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Type of Arrangement and Non-arrangement Transactions [Axis]
Arrangements and Non-arrangement Transactions [Domain]
Arrangements and Non-arrangement Transactions [Domain]
Glaxo Group Limited [Member]
Glaxo Group Limited [Member]
Glaxo Group Limited [Member]
Business Acquisition [Axis]
Business Acquisition [Axis]
Business Acquisition, Acquiree [Domain]
Business Acquisition, Acquiree [Domain]
Micromet Inc. [Member]
Micromet Inc [Member]
Micromet Inc.
Indefinite-lived Intangible Assets [Axis]
Indefinite-lived Intangible Assets [Axis]
Indefinite-lived Intangible Assets, Major Class Name [Domain]
Indefinite-lived Intangible Assets, Major Class Name [Domain]
IPR&D [Member]
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets [Line Items]
Amount of payments made in exchange for the early termination of the Collaboration Agreement
Collaborative Arrangement, Early Contract Termination Liability
Collaborative Arrangement, Early Contract Termination Liability
Indefinite-lived intangible assets reclassified
Indefinite-Lived Intangible Assets (Excluding Goodwill) Reclassified to Finite-Lived Intangible Assets
Indefinite-Lived Intangible Assets (Excluding Goodwill) Reclassified to Finite-Lived Intangible Assets
Impairment charge
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Amortization charges associated with finite-lived intangible assets
Amortization of Intangible Assets
Total estimated amortization of finite- lived intangible assets for 2015
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months
Total estimated amortization of finite- lived intangible assets for 2016
Finite-Lived Intangible Assets, Amortization Expense, Year Two
Total estimated amortization of finite- lived intangible assets for 2017
Finite-Lived Intangible Assets, Amortization Expense, Year Three
Total estimated amortization of finite-lived intangible assets for 2018
Finite-Lived Intangible Assets, Amortization Expense, Year Four
Total estimated amortization of finite-lived intangible assets for 2019
Finite-Lived Intangible Assets, Amortization Expense, Year Five
Goodwill and other intangible assets
Goodwill and Intangible Assets Disclosure [Text Block]
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table]
Schedule of Business Acquisitions, by Acquisition [Table]
Onyx Pharmaceuticals, Inc. [Member]
Onyx Pharmaceuticals, Inc. [Member]
Onyx Pharmaceuticals, Inc. [Member]
Product Rights [Member]
Filgrastim and Pegfilgrastim Rights [Member]
Filgrastim and Pegfilgrastim Rights [Member]
Business Acquisition [Line Items]
Aggregate acquisition date consideration to acquire an entity
Business Acquisition Cost Of Acquired Entity [Table Text Block]
Tabular disclosure of the aggregate acquisition date consideration to acquire an entity.
Schedule of recognized identified assets acquired and liabilities assumed
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
Business acquisition, pro forma information
Business Acquisition, Pro Forma Information [Table Text Block]
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table]
Schedule of Long-term Debt Instruments [Table]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Long-term Debt, Type [Domain]
Notes Payable [Member]
Notes Payable, Other Payables [Member]
Debt Instrument [Axis]
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
1.25% notes due 2017 (1.25% 2017 Notes)
One Point Two Five Percent Notes Due 2017 [Member]
One Point Two Five Percent Notes Due 2017 [Member]
2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Two Point Two Zero Percent Notes Due 2019 [Member]
Two Point Two Zero Percent Notes Due 2019 [Member]
3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Three Point Four Five Percent Notes Due 2020 [Member]
Three Point Four Five Percent Notes Due 2020 [Member]
4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Four Point One Zero Percent Notes Due 2021 [Member]
Four Point One Zero Percent Notes Due 2021 [Member]
3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Three Point Eight Seven Five Percent Notes Due 2021 [Member]
Three Point Eight Seven Five Percent Notes Due 2021 [Member]
3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Three Point Six Two Five Percent Notes Due 2022 [Member]
Three Point Six Two Five Percent Notes Due 2022 [Member]
Variable Rate [Axis]
Variable Rate [Axis]
Variable Rate [Domain]
Variable Rate [Domain]
LIBOR [Member]
London Interbank Offered Rate (LIBOR) [Member]
Derivative Instrument [Axis]
Derivative Instrument [Axis]
Derivative Contract [Domain]
Derivative Contract [Domain]
Interest Rate Swap, 2014 [Member]
Interest Rate Swap, 2014 [Member]
Interest Rate Swap, 2014 [Member]
Interest Rate Swap 2013 [Member]
Interest Rate Swap 2013 [Member]
Interest Rate Swap 2013 [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Derivative, effective interest rate
Derivative, Basis Spread on Variable Rate
Notional amount
Derivative, Notional Amount
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Award Type [Axis]
Award Type [Axis]
Award Type [Domain]
Equity Award [Domain]
Stock Options [Member]
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Closing price of our common stock on grant date (in usd per share)
Common Stock Fair Value
The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.
Expected volatility
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Risk-free interest rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Expected dividend yield
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]
Allowance for doubtful accounts [Roll Forward]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period
Valuation Allowances and Reserves, Balance
Additions charged to costs and expenses
Valuation Allowances and Reserves, Charged to Cost and Expense
Other additions
Valuation Allowances and Reserves, Charged to Other Accounts
Deductions
Valuation Allowances and Reserves, Deductions
Balance at end of period
Income Tax Disclosure [Abstract]
Current provision:
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal
Current Federal Tax Expense (Benefit)
State
Current State and Local Tax Expense (Benefit)
Foreign
Current Foreign Tax Expense (Benefit)
Total current provision
Current Income Tax Expense (Benefit)
Deferred provision (benefit):
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal
Deferred Federal Income Tax Expense (Benefit)
State
Deferred State and Local Income Tax Expense (Benefit)
Foreign
Deferred Foreign Income Tax Expense (Benefit)
Total deferred provision (benefit)
Deferred Income Tax Expense (Benefit)
Total provision
Income Tax Expense (Benefit)
Reconciliation between the federal statutory tax rate applied to income before income taxes and effective tax rate [Abstract]
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Federal statutory tax rate
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Foreign earnings, including earnings invested indefinitely
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent
Credits, Puerto Rico Excise Tax
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent
Credits, primarily federal R&D
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
State taxes
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
Audit settlements (federal, state, foreign)
Effective Income Tax Rate Reconciliation, Tax Settlement, Percent
Other, net
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Effective tax rate
Effective Income Tax Rate Reconciliation, Percent
Accounting Policies [Abstract]
Number of business segment
Number of Operating Segments
Revenue from External Customers by Products and Services [Table]
Revenue from External Customers by Products and Services [Table]
Products and Services [Axis]
Products and Services [Axis]
Products and Services [Domain]
Products and Services [Domain]
NEUPOGEN [Member]
NEUPOGEN [Member]
NEUPOGEN [Member]
Customer [Axis]
Customer [Axis]
Customer [Domain]
Customer [Domain]
U.S. federal government stockpiles [Member]
U.S. Federal Government Stockpiles [Member]
U.S. Federal Government Stockpiles [Member]
Revenue from External Customer [Line Items]
Revenue from External Customer [Line Items]
Product sales
Sales Revenue, Goods, Net
Restricted investments
Restricted Investments, Noncurrent
Fair Value Disclosures [Abstract]
Fair value measurement
Fair Value Disclosures [Text Block]
Investments, Debt and Equity Securities [Abstract]
Available-for-sale investments
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Business combinations
Business Combination Disclosure [Text Block]
Restricted Stock Units [Member]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Balance nonvested at beginning of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Vested (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Balance nonvested at end of period (in shares)
Restricted Stock Units, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Balance nonvested at beginning of period (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Granted (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Vested (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Forfeited (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Balance nonvested at end of period (in usd per share)
Earnings Per Share [Abstract]
Computation for basic and diluted earnings per share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Quarterly Financial Information Disclosure [Abstract]
Quarterly financial data (unaudited)
Schedule of Quarterly Financial Information [Table Text Block]
Plan Name [Axis]
Plan Name [Axis]
Plan Name [Domain]
Plan Name [Domain]
the Amended 2009 Plan [Member]
Amended and Restated 2009 Equity Incentive Plan [Member]
Amended and Restated 2009 Equity Incentive Plan [Member]
Schedule of Share-based Compensation Arrangement by Share-based Payment Award by Grant Date Type [Axis]
Share-based Compensation Arrangement by Share-based Payment Award by Grant Date Type [Axis]
Share-based Compensation Arrangement by Share-based Payment Award by Grant Date Type [Axis]
Share-based Compensation Arrangement by Share-based Payment Award by Grant Date Type [Domain]
Share-based Compensation Arrangement by Share-based Payment Award by Grant Date Type [Domain]
[Domain] for Share-based Compensation Arrangement by Share-based Payment Award by Grant Date Type [Axis]
Granted Prior to April 25, 2011 [Member]
Granted Prior to April Twenty Five Two Thousand Eleven [Member]
Granted Prior to April Twenty Five Two Thousand Eleven [Member]
Granted on April 25, 2011 through April 26, 2012 [Member]
Granted on April Twenty Five Two Thousand Eleven Through April Twenty Six Two Thousand Twelve [Member]
Granted on April Twenty Five Two Thousand Eleven Through April Twenty Six Two Thousand Twelve [Member]
Granted on and After April 26, 2010 [Member]
Granted on and After April Twenty Six Two Thousand Ten [Member]
Granted on and After April Twenty Six Two Thousand Ten [Member]
Granted Prior to April 26, 2010 [Member]
Granted Prior to April Twenty Six Two Thousand Ten [Member]
Granted Prior to April Twenty Six Two Thousand Ten [Member]
Stock Option and Restricted Stock Units [Member]
Stock Option and Restricted Stock Units [Member]
Stock option and restricted stock units.
Performance Units [Member]
Performance Units [Member]
Performance Units.
Number of shares of common stock authorized for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Amount by which the pool of available shares will be reduced for each stock option granted
Number Of Common Shares To Be Reduced For Each Stock Option Granted
Amount by which the pool of available shares will be reduced for each stock option granted.
The number of shares by which the pool of available shares will be reduced for other types of awards granted
Number of Common Shares to be Reduced For Other Types Of Awards Granted
Amount by which the pool of available shares will be reduced for other types of awards granted.
Number of shares added back for tax withholding on full value awards
Number of Shares Added Back for Tax Withholding on Full Value Awards
Number of Shares Added Back for Tax Withholding on Full Value Awards
The amount of common stock available under the plan for future grants and/or issuances (in shares)
Amount Of Common Stock Available Under Plan For Future Grants And Or Issuances
The amount of common stock available under the plan for future grants and/or issuances.
Period over which the grants of equity instruments vest
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period
Description of vesting of restricted stock units and stock options
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights
Weighted-average risk-free interest rate
Weighted average grant date fair value, granted (in usd per share)
Total fair value of units that vested during the year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value
Total unrecognized compensation cost related to nonvested awards
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Expiration period of stock options from date of grant
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period
Total intrinsic value of stock options exercised during the year
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Actual tax benefits realized from tax deductions from option exercises
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options
Number of common shares issued for each performance unit earned
Number of Common Shares Issued for Each Performance Unit Earned
Number of common shares issued for each performance unit earned.
Units outstanding (in shares)
Weighted average grant date fair value of units, outstanding
Weighted Average Grant Date Fair Value of Units Outstanding
Weighted average grant date fair value of units outstanding.
Units granted (in shares)
Units, vested (in shares)
Weighted average grant date fair value, vested (in usd per share)
Units, forfeited (in shares)
Weighted average grant date fair value, forfeited (in usd per share)
Segment Reporting [Abstract]
Schedule of Revenues from External Customers and Long-Lived Assets [Table]
Schedule of Revenues from External Customers and Long-Lived Assets [Table]
Geographical [Axis]
Geographical [Axis]
Geographical [Domain]
Geographical [Domain]
United States [Member]
UNITED STATES
Rest of the world (ROW) [Member]
ROW [Member]
ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues from External Customers and Long-Lived Assets [Line Items]
Geographical Information With Respect To Revenues [Abstract]
Geographical Information With Respect To Revenues [Abstract]
Geographical information with respect to revenues.
Revenues
Revenues
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments
Derivative Instruments and Hedging Activities Disclosure [Text Block]
Related Party Transactions [Abstract]
Related party transactions
Related Party Transactions Disclosure [Text Block]
Restructuring Type [Axis]
Restructuring Type [Axis]
Type of Restructuring [Domain]
Type of Restructuring [Domain]
Separation Costs [Member]
Employee Severance [Member]
Other [Member]
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve [Roll Forward]
Restructuring liabilities as of January 1, 2014
Restructuring Reserve
Expense
Restructuring Charges
Payments
Payments for Restructuring
Restructuring liabilities as of December 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments
Commitments and Contingencies Disclosure [Text Block]
Collaborative arrangements [Abstract]
Collaborative arrangements [Abstract]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
UCB [Member]
Collaborative Arrangements with UCB [Member]
Collaborative Arrangements with UCB [Member]
Research and development expense [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cost recoveries
Recovery of Direct Costs
Equity [Abstract]
Summary of activity under our stock repurchase program
Stock Repurchase Program [Table Text Block]
Tabular disclosure of activity under a stock repurchase program.
Components of Accumulated Other Comprehensive Income
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Reclassification out of Accumulated Other Comprehensive Income
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]
Components of stock-based compensation expense recognized in the Consolidated Statements of Income
Components of Stock based Compensation Expense [Table Text Block]
Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.
Restricted stock units Information
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]
Stock options information
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Weighted average assumptions used and the resulting weighted average grant date fair value of performance units
Share Based Compensation Arrangement By Share Based Payment Award Performance Units Fair Value Assumptions [Table Text Block]
Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.
Earnings per share
Earnings Per Share [Text Block]
Document and Entity Information [Abstract]
Document and Entity Information.
Shares of common stock held by directors and executive officers
Shares Common Stock Excluded From Public Float Calculation
Shares of common stock held by directors and executive officers.
RSUs [Member]
Performance units [Member]
Stock options [Member]
Components of stock-based compensation expense [Abstract]
Share-based Compensation [Abstract]
Total stock-based compensation expense, pre-tax
Share-based Compensation
Tax benefit from stock-based compensation expense
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense
Total stock-based compensation expense, net of tax
Stock Based Compensation Expense Net of Tax
Total stock-based compensation expense, net of tax.
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, Foreign currency translation
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax
Beginning balance, Cash flow hedges
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax
Beginning balance, Available-for-sale securities
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax
Beginning balance, Other
Accumulated Other Comprehensive Income Loss Other Net Of Tax
Accumulated other comprehensive income or loss, other items net of tax.
Beginning balance, AOCI
Accumulated Other Comprehensive Income (Loss), Net of Tax
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax
Unrealized gains (losses), Cash flow hedges
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax
Unrealized gains (losses), Available-for-sale securities
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax
Unrealized gains (losses), Other
Other Comprehensive Income Unrealized Arising During Period Before Reclassifications And Tax Others
Unrealized other comprehensive gain (loss) arising during period on other items, before reclassifications and tax.
Unrealized gains (losses), AOCI
Unrealized Losses Gains Before Reclassifications
Aggregate unrealized (losses)/gains arising during the period, before reclassifications and taxes.
Reclassification adjustments to income, Cash flow hedges
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax
Reclassification adjustments to income, Available-for-sale securities
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax
Reclassification adjustments to income, AOCI
Other Comprehensive Income Reclassification Adjustment To Income Before Tax
Total other comprehensive income reclassification adjustment to income before tax.
Other
Other Comprehensive Income Other
Other comprehensive income other, before tax.
Other, AOCI
Other Comprehensive Income Other Period Increase Decrease
Other, Accumulated other comprehensive income.
Income taxes, Foreign currency translation
Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax
Income taxes, Cash flow hedges
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax
Income taxes, Available-for-sale securities
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax
Income taxes, Other
Other Comprehensive Income Other Tax
Tax effect of other comprehensive income net of reclassification adjustments.
Income taxes, AOCI
Other Comprehensive Income (Loss), Tax
Ending balance, Foreign currency translation
Ending balance, Cash flow hedges
Ending balance, Available-for-sale securities
Ending balance, Other
Ending balance, AOCI
Components of Deferred Tax Assets and Liabilities [Abstract]
Components of Deferred Tax Assets and Liabilities [Abstract]
Deferred income tax assets:
Deferred Tax Assets, Net [Abstract]
NOL and credit carryforwards
Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.
Expense accruals
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities
Expenses capitalized for tax
Deferred Tax Assets, Tax Deferred Expense, Other
Stock-based compensation
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Other
Deferred Tax Assets, Other
Total deferred income tax assets
Deferred Tax Assets, Gross
Valuation allowance
Deferred Tax Assets, Valuation Allowance
Net deferred income tax assets
Deferred Tax Assets, Net of Valuation Allowance
Deferred income tax liabilities:
Deferred Tax Liabilities, Net [Abstract]
Acquired intangibles
Deferred Tax Liabilities, Intangible Assets
Other
Deferred Tax Liabilities, Other
Total deferred income tax liabilities
Deferred Tax Liabilities, Net
Total deferred income taxes, net
Deferred Tax Assets, Net
Stockholders' equity
Stockholders' Equity Note Disclosure [Text Block]
Schedule of Cross-Currency Swaps [Table]
Derivative [Table]
Hedging Relationship [Axis]
Hedging Relationship [Axis]
Hedging Relationship [Domain]
Hedging Relationship [Domain]
Cash flow hedge [Member]
Cash Flow Hedging [Member]
Cross-currency swap contracts [Member]
Cross Currency Swap Contracts [Member]
Cross currency swap contracts.
2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes) [Member]
Two Point One Two Five Percent Euro Notes Due 2019 [Member]
Two Point One Two Five Percent Euro Notes Due 2019 [Member]
5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]
Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]
4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Four Percent Pound Sterling Notes Due 2029 [Member]
Four Percent Pound Sterling Notes Due 2029 [Member]
Currency [Axis]
Currency [Axis]
All Currencies [Domain]
All Currencies [Domain]
Euro
Euro Member Countries, Euro
Sterling Pounds
United Kingdom, Pounds
Dollars
United States of America, Dollars
Derivative [Line Items]
Derivative [Line Items]
Notional Amount
Interest Rate
Derivative, Fixed Interest Rate
Amount available for stock repurchases under a board approved stock repurchase plan
Stock Repurchase Program, Remaining Authorized Repurchase Amount
Common stock, dividends declared per share (in usd per share)
Common Stock, Dividends, Per Share, Declared
Dividends paid per share (in usd per share)
Common Stock, Dividends, Per Share, Cash Paid
Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax
Income tax expense or (benefit) reclassification adjustments to income for cash flow hedges
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax
Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax
Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax
Preferred stock shares authorized (in shares)
Preferred Stock, Shares Authorized
Preferred stock, par value (in usd per share)
Preferred Stock, Par or Stated Value Per Share
Preferred stock, shares issued (in shares)
Preferred Stock, Shares Issued
Preferred stock, shares outstanding (in shares)
Preferred Stock, Shares Outstanding
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring [Member]
Fair Value, Measurements, Recurring [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Quoted prices in active markets for identical assets (Level 1) [Member]
Fair Value, Inputs, Level 1 [Member]
Significant other observable inputs (Level 2) [Member]
Fair Value, Inputs, Level 2 [Member]
Significant unobservable inputs (Level 3) [Member]
Fair Value, Inputs, Level 3 [Member]
Fair Value by Asset Class [Axis]
Asset Class [Axis]
Fair Value by Asset Class [Domain]
Asset Class [Domain]
U.S. Treasury securities [Member]
US Treasury Securities [Member]
Other government-related debt securities - U.S. [Member]
US Government Agencies Debt Securities [Member]
Other government-related debt securities - Foreign and other [Member]
Foreign Government Debt Securities [Member]
Corporate debt securities - Financial [Member]
Corporate Debt Securities Financial [Member]
Corporate debt securities financial Member.
Corporate debt securities - Industrial [Member]
Corporate Debt Securities Industrial [Member]
Corporate debt securities industrial Member.
Corporate debt securities - Other [Member]
Corporate Debt Securities Other [Member]
Corporate debt securities other.
Residential mortgage-backed securities [Member]
Residential Mortgage Backed Securities [Member]
Other mortgage- and asset-backed securities [Member]
Asset-backed Securities [Member]
Money market mutual funds [Member]
Money Market Funds [Member]
Other short-term interest-bearing securities [Member]
Other Short Term Interest Bearing Securities [Member]
Other short-term interest bearing securities.
Equity securities [Member]
Equity Securities [Member]
Foreign currency contracts [Member]
Foreign Exchange Contract [Member]
Interest rate swap contracts [Member]
Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets:
Assets, Fair Value Disclosure [Abstract]
Total available-for-sale investments
Available-for-sale Securities
Derivative Assets:
Derivative Assets Fair Value Disclosure [Abstract]
Derivative assets.
Foreign currency contracts
Foreign Currency Contract, Asset, Fair Value Disclosure
Interest rate swap contracts
Interest Rate Fair Value Hedge Asset at Fair Value
Total assets
Assets, Fair Value Disclosure
Liabilities:
Liabilities, Fair Value Disclosure [Abstract]
Derivative Liabilities:
Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]
Derivative financial instruments liabilities fair value disclosure.
Foreign currency contracts
Foreign Currency Contracts, Liability, Fair Value Disclosure
Interest rate swap contracts
Interest Rate Fair Value Hedge Liability at Fair Value
Contingent consideration obligations in connection with business combinations
Business Combination, Contingent Consideration, Liability
Total liabilities
Financial and Nonfinancial Liabilities, Fair Value Disclosure
Computation of basic and diluted earnings per share
Basic And Diluted Earning Per Share [Abstract]
Basic and diluted earning per share.
Income (Numerator):
Net Income (Loss) Attributable to Parent [Abstract]
Net income for basic and diluted EPS
Net Income (Loss) Attributable to Parent
Shares (Denominator):
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted-average shares for basic EPS
Weighted Average Number of Shares Outstanding, Basic
Effect of dilutive securities (in shares)
Weighted Average Number Diluted Shares Outstanding Adjustment
Weighted-average shares for diluted EPS
Weighted Average Number of Shares Outstanding, Diluted
Basic EPS (in usd per share)
Earnings Per Share, Basic
Diluted EPS (in usd per share)
Earnings Per Share, Diluted
Schedule of Available-for-sale Securities [Table]
Schedule of Available-for-sale Securities [Table]
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Major Types of Debt and Equity Securities [Domain]
Total interest-bearing securities [Member]
Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Fair Values Of Available For Sale Investments By Type Of Security [Abstract]
Fair values of available for sale investments by type of security Abstract.
Amortized cost
Available-for-sale Securities, Amortized Cost Basis
Gross unrealized gains
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
Gross unrealized losses
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax
Total available-for-sale investments, fair value
Marketing-related Rights [Member]
Marketing-Related Intangible Assets [Member]
Business Acquisition [Line Items]
Total consideration transferred
Business Combination, Consideration Transferred, Including Settlement of Pre-existing Relationship
Business Combination, Consideration Transferred, Including Settlement of Pre-existing Relationship
Settlement of preexisting relationship at fair value
Business Combination, Settlement of Pre-existing Relationship
Business Combination, Settlement of Pre-existing Relationship
Total consideration transferred to acquire the Product Rights
Business Combination, Consideration Transferred
Finite-lived intangible assets
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles
Goodwill
Goodwill
Other assets
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets
Total consideration
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Antidilutive securities excluded from computation of diluted earnings per share, amount
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Neulasta [Member]
Neulasta [Member]
Neulasta.
ENBREL [Member]
ENBREL [Member]
ENBREL.
XGEVA [Member]
XGEVA [Member]
XGEVA.
Prolia [Member]
Prolia [Member]
Prolia.
EPOGEN [Member]
EPOGEN [Member]
EPOGEN.
Aranesp [Member]
Aranesp [Member]
Aranesp.
Sensipar Mimpara [Member]
Sensipar Mimpara [Member]
Sensipar (Mimpara).
Vectibix [Member]
Vectibix [Member]
Vectibix.
Nplate [Member]
Nplate [Member]
Nplate.
Kyprolis [Member]
Kyprolis [Member]
Kyprolis [Member]
BLINCYTO [Member]
BLINCYTO [Member]
BLINCYTO [Member]
Other [Member]
Other Countries [Member]
Other Countries.
Revenues [Abstract]
Revenues [Abstract]
Other revenues
Other Revenue, Net
Total revenues
Revenues
Revenue from External Customers by Products and Services [Table Text Block]
Geographical information with respect to revenues and long-lived assets
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
Revenues earned from major customers
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]
1.875% notes due 2014 (1.875% 2014 Notes) [Member]
One Point Eight Seven Five Percent Notes Due 2014 [Member]
One Point Eight Seven Five Percent Notes Due 2014
4.85% notes due 2014 (4.85% 2014 Notes) [Member]
Four Point Eight Five Percent Notes Due 2014 [Member]
Four Point Eight Five Percent Notes Due 2014 [Member]
2.30% notes due 2016 (2.30% 2016 Notes) [Member]
Two Point Three Zero Percent Notes Due 2016 [Member]
Two Point Three Zero Percent Notes Due 2016 [Member]
2.50% notes due 2016 (2.50% 2016 Notes) [Member]
Two Point Five Zero Percent Notes Due 2016 [Member]
Two Point Five Zero Percent Notes Due 2016 [Member]
Floating Rate Notes due 2017 [Member]
Floating Rate Notes Due 2017 [Member]
Floating Rate Notes Due 2017 [Member]
2.125% notes due 2017 (2.125% 2017 Notes)
Two Point One Two Five Percent Notes Due 2017 [Member]
Two Point One Two Five Percent Notes Due 2017 [Member]
5.85% notes due 2017 (5.85% 2017 Notes) [Member]
Five Point Eight Five Percent Notes Due 2017 [Member]
Five Point Eight Five Percent Notes Due 2017 [Member]
6.15% notes due 2018 (6.15% 2018 Notes)
Six Point One Five Percent Notes Due 2018 [Member]
Six Point One Five Percent Notes Due 2018 [Member]
Master Repurchase Agreement obligation due 2018 [Member]
Master Repurchase Agreement Obligation Due 2018 [Member]
Master Repurchase Agreement Obligation Due 2018 [Member]
Term Loan Due 2018 [Member]
Term Loan Due 2018 [Member]
Term Loan Due 2018 [Member]
4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes) [Member]
Four Point Three Seven Five Percent Euro Notes Due 2018 [Member]
Four Point Three Seven Five Percent Euro Notes Due 2018 [Member]
Floating Rate Notes due 2019 [Member]
Floating Rate Notes Due 2019 [Member]
Floating Rate Notes Due 2019 [Member]
5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Five Point Seven Zero Percent Notes Due 2019 [Member]
Five Point Seven Zero Percent Notes Due 2019 [Member]
4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Four Point Five Zero Percent Notes Due 2020 [Member]
Four Point Five Zero Percent Notes Due 2020 [Member]
3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Three Point Six Two Five Percent Notes Due 2024 [Member]
Three Point Six Two Five Percent Notes Due 2024 [Member]
6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Six Point Three Seven Five Percent Notes Due 2037 [Member]
Six Point Three Seven Five Percent Notes Due 2037 [Member]
6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Six Point Nine Zero Percent Notes Due 2038 [Member]
Six Point Nine Zero Percent Notes Due 2038 [Member]
6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Six Point Four Zero Percent Notes Due 2039 [Member]
Six Point Four Zero Percent Notes Due 2039 [Member]
5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Five Point Seven Five Percent Notes Due 2040 [Member]
Five Point Seven Five Percent Notes Due 2040 [Member]
4.95% notes due 2041 (4.95% 2041 Notes) [Member]
Four Point Nine Five Percent Notes Due 2041 [Member]
Four Point Nine Five Percent Notes Due 2041 [Member]
5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Five Point One Five Percent Notes Due 2041 [Member]
Five Point One Five Percent Notes Due 2041 [Member]
5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Five Point Six Five Percent Notes Due 2042 [Member]
Five Point Six Five Percent Notes Due 2042 [Member]
5.375% notes due 2043 (5.375% 2043 Notes) [Member]
Five Point Three Seven Five Percent Notes Due 2043 [Member]
Five Point Three Seven Five Percent Notes Due 2043 [Member]
Carrying values of long-term borrowings
Long-term Debt, by Current and Noncurrent [Abstract]
Notes payable, current
Notes Payable, Current
Notes payable, noncurrent
Notes Payable, Noncurrent
Loans payable to bank
Loans Payable to Bank, Current
Loans payable to bank, noncurrent
Loans Payable to Bank, Noncurrent
Other notes
Other Notes
Carrying value of the current and noncurrent portion of notes payable which were initially due after one year or beyond the normal operating cycle, if longer, and which are not otherwise defined in the taxonomy.
Total debt
Long-term Debt
Less current portion
Long-term Debt, Current Maturities
Total noncurrent debt
Long-term Debt, Excluding Current Maturities
Less than 12 months, Fair value
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
Less than 12 months, Unrealized losses
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
12 months or greater, Fair value
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
12 months or greater, Unrealized losses
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Licensing Rights [Member]
Licensing Agreements [Member]
R&D Technology Rights [Member]
Acquired Research And Development Technology Rights [Member]
Acquired research and development technology rights.
Marketing-related Rights [Member]
Other Intangible Assets [Member]
Finite-lived intangible assets:
Finite-Lived Intangible Assets, Net [Abstract]
Gross carrying amount
Finite-Lived Intangible Assets, Gross
Accumulated amortization
Finite-Lived Intangible Assets, Accumulated Amortization
Intangible assets, net
Finite-Lived Intangible Assets, Net
Indefinite-lived intangible assets:
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Indefinite-lived intangible assets
Indefinite-Lived Intangible Assets (Excluding Goodwill)
Identifiable intangible assets
Identifiable Intangible Assets Gross
Identifiable intangible assets gross.
Accumulated amortization
Identifiable Intangible Assets Accumulated Amortization
Identifiable intangible assets accumulated amortization.
Identifiable intangible assets, net
Intangible Assets, Net (Excluding Goodwill)
Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]
Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]
Hedging Designation [Axis]
Hedging Designation [Axis]
Hedging Designation [Domain]
Hedging Designation [Domain]
Derivatives designated as hedging instrument [Member]
Designated as Hedging Instrument [Member]
Derivatives not designated as hedging instrument [Member]
Not Designated as Hedging Instrument [Member]
Interest rate swap contracts [Member]
Interest Rate Contract [Member]
Balance Sheet Location [Axis]
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Balance Sheet Location [Domain]
Other current assets/Other noncurrent assets [Member]
Other Current Noncurrent Assets [Member]
Other current assets/other non-current assets.
Other current assets [Member]
Other Current Assets [Member]
Accrued liabilities/Other noncurrent liabilities [Member]
Accrued Liabilities Other Non Current Liabilities [Member]
Accrued liabilities/other non-current liabilities.
Accrued liabilities [Member]
Accrued Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivatives, Fair Value [Line Items]
Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets
Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]
Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.
Assets
Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]
Total derivative assets, fair value
Derivative Asset, Fair Value, Gross Asset
Liabilities
Derivative Liability, Fair Value, Amount Not Offset Against Collateral [Abstract]
Total derivative liabilities, fair value
Derivative Liability, Fair Value, Gross Liability
Inventory Disclosure [Abstract]
Inventories
Inventory, Net, Items Net of Reserve Alternative [Abstract]
Raw materials
Inventory, Raw Materials, Net of Reserves
Work in process
Inventory, Work in Process, Net of Reserves
Finished goods
Inventory, Finished Goods, Net of Reserves
Total inventories
Inventory, Net
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net income
Depreciation and amortization
Depreciation, Depletion and Amortization
Stock-based compensation expense
Deferred income taxes
Increase (Decrease) in Deferred Income Taxes
Property, plant and equipment impairments
Impairment of Long-Lived Assets Held-for-use
Other items, net
Other Noncash Income (Expense)
Changes in operating assets and liabilities, net of acquisitions:
Increase (Decrease) in Operating Capital [Abstract]
Trade receivables, net
Increase (Decrease) in Accounts Receivable
Inventories
Increase (Decrease) in Inventories
Other assets
Increase (Decrease) in Other Operating Assets
Accounts payable
Increase (Decrease) in Accounts Payable
Accrued income taxes
Increase (Decrease) in Income Taxes Payable
Legal reserve
Increase Decrease In Litigation Reserve
Increase decrease in litigation reserve.
Other liabilities
Increase (Decrease) in Other Operating Liabilities
Net cash provided by operating activities
Net Cash Provided by (Used in) Operating Activities
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
Cash paid for acquisitions, net of cash acquired
Payments to Acquire Businesses, Net of Cash Acquired
Purchases of intangible assets
Payments to Acquire Intangible Assets
Purchases of marketable securities
Payments to Acquire Available-for-sale Securities
Proceeds from sales of marketable securities
Proceeds from Sale of Available-for-sale Securities
Proceeds from maturities of marketable securities
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities
Change in restricted investments, net
Increase (Decrease) of Restricted Investments
Other
Payments for (Proceeds from) Other Investing Activities
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Net proceeds from issuance of debt
Proceeds from Issuance of Long-term Debt
Repayment of debt
Repayments of Long-term Debt
Repurchases of common stock
Payments for Repurchase of Common Stock
Dividends paid
Payments of Ordinary Dividends, Common Stock
Net proceeds from issuance of common stock in connection with the Company's equity award programs
Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options
Other
Proceeds from (Payments for) Other Financing Activities
Net cash (used in) provided by financing activities
Net Cash Provided by (Used in) Financing Activities
(Decrease) increase in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents at beginning of period
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents at end of period
Fair values of available-for-sale debt security investments by contractual maturity
Fair Values Of Available For Sale Investments By Contractual Maturity [Abstract]
Fair values of available-for-sale investments by contractual maturity.
Maturing in one year or less
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value
Maturing after one year through three years
Maturing After One Year Through Three Years
This item represents the fair value of debt securities which are expected to mature after one year through three years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.
Maturing after three years through five years
Maturing After Three Years Through Five Years
This item represents the fair value of debt securities which are expected to mature after three years through five years of the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.
Maturing after five years through ten years
Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value
Maturing after ten years
Available-for-sale Securities, Debt Maturities, after Ten Years, Fair Value
Mortgage- and asset-backed securities
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value
Total available-for-sale investments, fair value
Derivative [Table]
Fair Value by Asset Class [Domain]
Other government-related and corporate debt securities [Member]
Other Government-related and Corporate Debt Securities [Member]
Other Government-related and Corporate Debt Securities [Member]
Biovex Group Inc [Member]
Biovex Group Inc [Member]
BioVex Group Inc.
Milestone Payment [Axis]
Milestone Payment [Axis]
Milestone Payment [Axis]
Milestone Payment [Domain]
Milestone Payment [Domain]
[Domain] for Milestone Payment [Axis]
Due to Filing of BLA in the US [Member]
Due to Filing of BLA in the US [Member]
Due to Filing of BLA in the US [Member]
Upon First Commercial Sale in the US [Member]
Upon First Commercial Sale in the US [Member]
Upon First Commercial Sale in the US [Member]
Upon Achievement of Agreed Level of Worldwide Sales [Member]
Upon Achievement of Agreed Level of Worldwide Sales [Member]
Upon Achievement of Agreed Level of Worldwide Sales [Member]
Upon Achievement of Certain Other Regulatory and Sales-related Milestones [Member]
Upon Achievement of Certain Other Regulatory and Sales-related Milestones [Member]
Upon Achievement of Certain Other Regulatory and Sales-related Milestones [Member]
Fair Value Measurement (Textual) [Abstract]
Fair Value Measurement (Textual) [Abstract]
Fair value measurement.
Investment maturity period
Investment Maturity Period
Investment Maturity Period
Length of time hedged in foreign currency contracts
Maximum Length of Time, Foreign Currency Cash Flow Hedge
Maximum additional consideration due contingent on certain milestones
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High
Additional contingent consideration upon achievement of milestones
Business Combination, Additional Contingent Consideration Upon Achievement of Milestones
Business Combination, Additional Contingent Consideration Upon Achievement of Milestone
Change in fair values of contingent consideration obligations
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
Number of milestone payments
Business Combination, Contingent Consideration Arrangements, Number of Milestone Payments
Business Combination, Contingent Consideration Arrangements, Number of Milestone Payments
Settlement of contingent consideration
Business Combination, Contingent Consideration Arrangements, Settlement of Contingent Consideration
Business Combination, Contingent Consideration Arrangements, Settlement of Contingent Consideration
Aggregate fair value of long-term debt, including current portion
Notes Payable, Fair Value Disclosure
Carrying value of long-term debt, including current portion
Income taxes
Income Tax Disclosure [Text Block]
Income Statement [Abstract]
Revenues:
Other revenues
Operating expenses:
Costs and Expenses [Abstract]
Cost of sales
Cost of Goods Sold
Research and development
Research and Development Expense (Excluding Acquired in Process Cost)
Selling, general and administrative
Selling, General and Administrative Expense
Other
Other General Expense
Total operating expenses
Costs and Expenses
Operating income
Operating Income (Loss)
Interest expense, net
Interest Expense, Debt
Interest and other income, net
Nonoperating Income (Expense)
Income before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest
Provision for income taxes
Net income
Earnings per share:
Basic (in usd per share)
Diluted (in usd per share)
Shares used in the calculation of earnings per share:
Basic (in shares)
Diluted (in shares)
Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed
Cash and cash equivalents
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Marketable securities
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities
Inventories
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory
Indefinite-lived intangible assets - IPR&D
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets
Convertible debt
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Convertible Debt
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Convertible Debt
Assumed contingent consideration
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability
Deferred income taxes, net
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent
Other assets (liabilities), net
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities Acquired, Net
The amount of acquisition cost of a business combination allocated to identifiable other assets and liabilities, net.
Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]
Derivative Instruments, Gain (Loss) [Table]
Foreign currency option contracts [Member]
Options Held [Member]
Foreign currency and cross currency swap contracts [Member]
Foreign Currency and Cross Currency Swaps [Member]
Foreign currency and cross currency swaps.
Forward interest rate contracts [Member]
Other Contract [Member]
Interest rate swap [Member]
Rate adjustment to LIBOR on Interest Rate Swap Agreements [Member]
Rate Adjustment To Libor On Interest Rate Swap Agreements [Member]
Rate Adjustment To Libor On Interest Rate Swap Agreements.
Foreign currency forward contracts [Member]
Forward Contracts [Member]
5.50% 2026 pound sterling Notes [Member]
4.00% 2029 pound sterling Notes [Member]
Three-Month London Interbank Offered Rate (LIBOR) [Member]
Three-Month London Interbank Offered Rate (LIBOR) [Member]
Three-Month London Interbank Offered Rate (LIBOR) [Member]
Cash Flow Statement Location [Axis]
Cash Flow Statement Location [Axis]
Cash Flow Statement.
Cash Flow Statement [Domain]
Cash Flow Statement [Domain]
Cash Flow Statement.
Net cash provided by operating activities [Member]
Net Cash Provided By Operating Activities [Member]
Net cash provided by operating activities.
Interest expense, net [Member]
Interest Expense [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments (Textual) [Abstract]
Derivative instruments (Textual) [Abstract]
Derivative instruments.
Stated contractual interest rate on note
Debt Instrument, Interest Rate, Stated Percentage
Amounts expected to be reclassified from accumulated other comprehensive income into earnings over the next 12 months - gains on foreign currency and cross currency swap
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months
Amounts expected to be reclassified from accumulated other comprehensive income into earnings over the next 12 months - gain (loss)
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net
Derivative lower range variable interest rate
Derivative, Lower Range of Basis Spread on Variable Rate
Derivative higher range variable interest rate
Derivative, Higher Range of Basis Spread on Variable Rate
Receipt from counterparties upon termination of interest rate swap contracts
Gain On Discontinuation Of Interest Rate Fair Value Hedge
The amount of cash received from counterparties for the gain realized upon discontinuation of interest rate fair value hedge. The amount is the unamortized adjustment regarding an interest-bearing hedged item made under the interest rate fair value hedge that is amortized into earnings over the remaining life of the hedged item.
Unrealized gain (loss) on the hedged debt
Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge
Offsetting unrealized gain (loss) on related interest rate swaps
Increase (Decrease) in Fair Value of Interest Rate Fair Value Hedging Instruments
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Customer [Domain]
AmerisourceBergen Corporation [Member]
Customer One [Member]
Customer one.
McKesson Corporation [Member]
Customer Two [Member]
Customer two.
Cardinal Health, Inc. [Member]
Customer Three [Member]
Customer three.
Segment Reporting Information [Line Items]
Segment Reporting Information [Line Items]
Amount due from major customer (as defined) as a percentage of gross trade receivables
Threshold for Disclosure of Amounts Due From Major Customers
Amount due from major customer (as defined) as a percentage of gross trade receivables.
Number of major customers (as defined) accounting for more than 10% of total revenue
Number of Customers Accounting for More Than Ten Percent of Revenue
Number of major customers (as defined) accounting for more than 10% of total revenue.
Threshold as a percentage of total revenues for determining a major customer for additional disclosures
Threshold for Disclosure of Product Sales to Major Customers
Threshold as a percentage of total revenues for determining a major customer for additional disclosures.
Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis
Percentage Of Combined Worldwide Gross Revenues From Major Customers
Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.
Percentage of United States gross product sales derived from major customers (as defined) on a combined basis
Percentage of Combined Gross Product Sales from Major Customers
Percentage of United States gross product sales derived from major customers (as defined) on a combined basis.
Major customers (as defined) accounting for more than 10% of gross trade receivables
Number of Customers Accounting for More Than Ten Percent of Gross Trade Receivables
Major customers (as defined) accounting for more than 10% of gross trade receivables.
Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables
Percentage of Combined Net Trade Receivables from Major Customers
Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.
Percentage of net trade receivables due from customers located outside the United States, primarily in Europe
Percentage of Net Amount Due from Customers Located Outside Domestic Location
Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.
Reclassification out of Accumulated Other Comprehensive Income [Axis]
Reclassification out of Accumulated Other Comprehensive Income [Axis]
Reclassification out of Accumulated Other Comprehensive Income [Domain]
Reclassification out of Accumulated Other Comprehensive Income [Domain]
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) by Hedging Relationship [Axis]
Derivatives in cash flow hedging relationships [Member]
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts [Abstract]
Statements Of Income And Effective Portion Of Gain Loss Reclassified From Accumulated Other Comprehensive Income Into Income For Our Cash Flow Hedge Contracts [Abstract]
Statements of income and effective portion of gain (loss) reclassified from accumulated other comprehensive income into income for our cash flow hedge contracts.
The amount of gain (loss) recognized in interest and other income, net
Other Income
The amount of gain (loss) recognized in interest expense, net
Interest Expense
Total
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Schedule of goodwill
Schedule of Goodwill [Table Text Block]
Schedule of identifiable intangible assets
Schedule Of Intangible Assets [Table Text Block]
Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Change in carrying amounts of contingent consideration obligations
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]
Reclassification out of Accumulated Other Comprehensive Income [Table]
Reclassification out of Accumulated Other Comprehensive Income [Table]
Equity Components [Axis]
Equity Components [Axis]
Equity Component [Domain]
Equity Component [Domain]
Cash flow hedges [Member]
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Available-for-sale securities [Member]
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net
Interest expense, net
Tax benefit (expense)
Inventories
Schedule of Inventory, Current [Table Text Block]
Volatility
Fair value of unit (in usd per share)
Property, Plant and Equipment [Abstract]
Property, plant and equipment
Property Plant and Equipment [Table Text Block]
Tabular disclosure of the useful life, gross carrying value and aggregate accumulated depreciation and amortization of tangible long-lived assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
Stock Options [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Balance unexercised at beginning of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Expired/forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Balance unexercised at end of period (in shares)
Stock Options, Weighted Average Exercise Price [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Balance unexercised at beginning of period (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Granted (in usd per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Exercised (in usd per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Expired/forfeited (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Balance unexercised at end of period (in shares)
Stock options information [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Vested or expected to vest (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Exercisable (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Weighted-average exercise price, vested or expected to vest (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Weighted-average exercise price, exercisable (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted-average remaining contractual life (years), unexercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life (years), vested or expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life (years), exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Aggregate intrinsic value, unexercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate intrinsic value, vested or expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Aggregate intrinsic value, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Quarterly financial data (unaudited)
Quarterly Financial Information [Text Block]
Segment information
Segment Reporting Disclosure [Text Block]
Pfizer Inc [Member]
Collaborative Arrangement With Pfizer Inc [Member]
Collaborative arrangement with Pfizer Inc.
Period required to pay percentage of net sales, after expiration of agreement in years
Period Required To Pay Percentage Of Net Sales
Period required to pay percentage of net sales after expiration of agreement in years.
Maximum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013
Maximum Annual Net Sales Payable Under Collaborative Arrangements Percentage
Maximum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013.
Minimum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013
Minimum Annual Net Sales Payable Under Collaborative Arrangements Percentage
Minimum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013.
Profit share and royalty expense, net of partner portion of selling and marketing expense
Collaborative Arrangement, Profit Share and Royalty Expense, Net of Partner Portion of Selling and Marketing Expense
Collaborative Arrangement, Profit Share and Royalty Expense, Net of Partner Portion of Selling and Marketing Expense
Royalty expense
Royalty Expense
Business
Nature Of Operations [Policy Text Block]
Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".
Principles of consolidation
Consolidation, Policy [Policy Text Block]
Use of estimates
Use of Estimates, Policy [Policy Text Block]
Product sales
Revenue Recognition, Sales of Goods [Policy Text Block]
Other revenues
Other Revenues [Policy Text Block]
Describes an entity's accounting policy for other revenues.
Multiple-deliverable revenue arrangements
Revenue Recognition, Multiple-deliverable Arrangements, Description [Policy Text Block]
Research and development costs
Research and Development Expense, Policy [Policy Text Block]
Selling, general and administrative costs
Selling, General and Administrative Expenses, Policy [Policy Text Block]
Stock-based compensation
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Income taxes
Income Tax, Policy [Policy Text Block]
Business combinations
Business Combinations Policy [Policy Text Block]
Cash equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Available-for-sale investments
Investment, Policy [Policy Text Block]
Inventories
Inventory, Policy [Policy Text Block]
Derivatives
Derivatives, Policy [Policy Text Block]
Property, plant and equipment, net
Property, Plant and Equipment, Policy [Policy Text Block]
Goodwill and other intangible assets
Goodwill and Intangible Assets, Policy [Policy Text Block]
Restricted investments
Restricted Investments [Policy Text Block]
Restricted Investments [Policy Text Block]
Contingencies
Commitments and Contingencies, Policy [Policy Text Block]
Foreign currency translation
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Recent accounting pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Property, plant and equipment
Property, Plant and Equipment Disclosure [Text Block]
Minimum future rental commitments under non-cancelable operating leases
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015
Operating Leases, Future Minimum Payments Due, Next Twelve Months
2016
Operating Leases, Future Minimum Payments, Due in Two Years
2017
Operating Leases, Future Minimum Payments, Due in Three Years
2018
Operating Leases, Future Minimum Payments, Due in Four Years
2019
Operating Leases, Future Minimum Payments, Due in Five Years
Thereafter
Operating Leases, Future Minimum Payments, Due Thereafter
Total minimum operating lease commitments
Operating Leases, Future Minimum Payments Due
Statement, Geographical [Axis]
Puerto Rico [Member]
PUERTO RICO
Long Lived Assets [Abstract]
Long Lived Assets [Abstract]
Long lived assets.
Total long-lived assets
Property, Plant and Equipment, Net
Stock Repurchase Program [Table]
Stock Repurchase Program [Table]
Stock Repurchase Program.
Share Repurchase Program [Axis]
Share Repurchase Program [Axis]
Share Repurchase Program [Domain]
Share Repurchase Program [Domain]
Stock Repurchase Program [Member]
Stock Repurchase Program [Member]
-- None. No documentation exists for this element. --
Statement [Line Items]
Statement [Line Items]
Stock repurchase program
Stock Repurchase Program [Abstract]
Stock repurchase program.
Stock repurchases (in shares)
Stock Repurchased and Retired During Period, Shares
Stock repurchases
Stock Repurchased During Period Under Stock Repurchase Program Value
The value of stock repurchased during the period under a stock repurchase program.
Interest and other income, net [Member]
Interest And Other Income [Member]
Interest and other income.
Location in the Condensed Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for our derivative instruments not designated as hedging instruments
Condensed Consolidated Statements Of Income And Amount Of Gain Recognized In Income For Derivative Instruments Not Designated As Hedging Instruments [Abstract]
Condensed Consolidated Statements of Income and the amount of gain recognized in income for the derivative instruments not designated as hedging instruments.
Derivatives not designated as hedging instruments
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts [Abstract]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net [Abstract]
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net
Stock-based compensation
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Loss Contingencies [Table]
Loss Contingencies [Table]
Scenario [Axis]
Scenario [Axis]
Scenario, Unspecified [Domain]
Scenario, Unspecified [Domain]
Scenario, Forecast [Member]
Scenario, Forecast [Member]
Litigation Case [Axis]
Litigation Case [Axis]
Litigation Case Type [Domain]
Litigation Case [Domain]
Sanofi/Regeneron Patent Litigation [Member]
Sanofi/Regeneron Patent Litigation [Member]
Sanofi/Regeneron Patent Litigation [Member]
Sandoz Filgrastim Litigation [Member]
Sandoz Filgrastim Litigation [Member]
Sandoz Filgrastim Litigation [Member]
Superior Court State of California [Member]
Superior Court State of California [Member]
Superior Court State of California [Member]
In re Amgen Inc. Securities Litigation [Member]
In re Amgen Inc. Securities Litigation [Member]
In re Amgen Inc. Securities Litigation [Member]
Larson v. Sharer, et al [Member]
Larson v. Sharer, et al [Member]
Larson v. Sharer, et al [Member]
Federal Derivative Litigation [Member]
Federal Derivative Ligiation [Member]
Federal Derivative Ligiation [Member]
Ramos v. Amgen Inc., et al. [Member]
Ramos v. Amgen Inc., et al. [Member]
Ramos v. Amgen Inc., et al. [Member]
Harris, et. al. v. Amgen Inc. [Member]
Harris, et. al. v. Amgen Inc. [Member]
Harris, et. al. v. Amgen Inc. [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon
Gain Contingency, Patents Allegedly Infringed upon, Number
Number of motions to be heard
Gain Contingency, Pending Claims, Number
Gain Contingency, Pending Claims, Number
Number of plaintiffs
Loss Contingency, Number of Plaintiffs
Number of purported class actions
Loss Contingency, Pending Claims, Number
Number of stockholder complaints
Loss, Contingency, Number of Stockholder Complaints Consolidated
Loss, Contingency, Number of Stockholder Complaints Consolidated
Length of time Federal Derivative Litigation cases stayed after Amgen Inc. Securities Litigation
Loss Contingency, Length Stay on Case Subsequent to Related Action
Loss Contingency, Length Stay on Case Subsequent to Related Action
Number of new defendants
Loss Contingency, Number of New Defendants
Loss Contingency, Number of New Defendants
Number of additional plaintiffs
Loss Contingency, Number of Additional Plaintiffs
Loss Contingency, Number of Additional Plaintiffs
Future rental commitments for abandoned leases
Future Rental Commitments For Abandoned Leases
Future rental commitments for abandoned leases.
Rental expense on operating leases
Rental Expense On Operating Leases
Rental expense incurred for assets leased under operating leases including furniture and equipment included in operating expenses.
Carrying values and the fixed contractual coupon rates of long-term borrowings
Schedule of Long-term Debt Instruments [Table Text Block]
Schedule of interest rate derivatives
Schedule of Interest Rate Derivatives [Table Text Block]
Aggregate contractual maturities of long-term debt obligations
Schedule of Maturities of Long-term Debt [Table Text Block]
Minimum future rental commitments under non-cancelable operating leases
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Related Party [Axis]
Related Party [Axis]
Related Party [Domain]
Related Party [Domain]
Kirin-Amgen [Member]
Limited Partner [Member]
Other revenues [Member]
Other Revenues [Member]
Other revenues.
Noncurrent Other Assets [Member]
Other Assets [Member]
Accrued Liabilities [Member]
Other Current Assets [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Ownership interest (in percent) in related party
Equity Method Investment, Ownership Percentage
Company's share of profits (losses) of related party
Income (Loss) from Equity Method Investments
Approximate carrying value of the company's equity method investment
Equity Method Investments
Royalties earned by related party from Amgen
Related Party Transaction, Expenses from Transactions with Related Party
Revenues earned by Amgen from related party
Revenue from Related Parties
Payments that may be received upon the achievement of various substantive success-based development and regulatory approval milestones
Commercial Milestone Payments Receivable Under Collaborative Arrangements
Milestone payments that may be received upon the achievement of various success-based milestones.
Cost recoveries by Amgen from related party
Related Party Transaction Cost Recoveries From Transactions With Related Party
Cost recoveries recorded as reductions in expenses realized from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.
Amount due to related party
Due to Related Parties, Current
Amount due from related party
Due from Related Parties, Current
deCODE Genetics [Member]
de CODE Genetics [Member]
de CODE Genetics [Member]
Kai Pharmaceuticals [Member]
Kai Pharmaceuticals [Member]
Kai pharmaceuticals member.
Mustafa Nevzat Pharmaceuticals [Member]
Mustafa Nevzat Pharmaceuticals [Member]
Mustafa nevzat pharmaceuticals.
Deferred income taxes, net
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax, Net
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax, Net
Total consideration
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Revenue, Major Customer [Line Items]
Revenue, Major Customer [Line Items]
Revenues Earned from Major Customers [Abstract]
Revenues Earned from Major Customers [Abstract]
Revenues earned from major customers.
Gross product sales to major customer (as defined) as a percentage of total gross revenues
Percentage of Gross Revenues
Gross product sales to major customer (as defined) as a percentage of total gross revenues.
Gross product sales to major customer (as defined) as a percentage of U.S. gross product sales
Percentage of Gross Domestic Product Sales
Gross product sales to major customer (as defined) as a percentage of U.S. gross product sales.
Available-for-sale investments [Member]
Available For Sales Investments [Member]
Available for sales investments.
Investment, Name [Axis]
Investment, Name [Axis]
Investment, Name [Domain]
Investment, Name [Domain]
ATL Holdings [Member]
ATL Holdings [Member]
ATL Holdings [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.
Cash and cash equivalents
Marketable securities
Available-for-sale Securities, Current
Other assets - noncurrent
Other Assets, Noncurrent
Restricted investments
Schedule of Equity Method Investments [Table]
Schedule of Equity Method Investments [Table]
Reclassifications [Axis]
Reclassifications [Axis]
Reclassifications [Axis]
Reclassifications [Domain]
Reclassifications [Domain]
[Domain] for Reclassifications [Axis]
Reclassified to Restricted Investments [Member]
Restricted Investments [Member]
Restricted Investments [Member]
Schedule of Equity Method Investments [Line Items]
Schedule of Equity Method Investments [Line Items]
Interest receivable
Restricted Interest Receivable
Restricted Interest Receivable
Available-for-sale investments (Textual) [Abstract]
Available-for-sale securities (Textual) [Abstract]
Available for sale securities.
Cash
Cash
Total realized gains
Available-for-sale Securities, Gross Realized Gains
Total realized losses
Available-for-sale Securities, Gross Realized Losses
Pro forma net revenues
Business Acquisition, Pro Forma Revenue
Pro forma net income
Business Acquisition, Pro Forma Net Income (Loss)
Income Taxes (Textual) [Abstract]
Income Taxes (Textual) [Abstract]
Income taxes.
Increase in valuation allowance for deferred tax assets
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Interest and penalties related to unrecognized tax benefits recognized in income tax provision
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Accrued interest and penalties associated with unrecognized tax benefits
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
Total foreign income before income taxes
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Income taxes paid
Income Taxes Paid
Tax Credit Carryforward [Table]
Tax Credit Carryforward [Table]
Valuation Allowances and Reserves [Axis]
Valuation Allowances and Reserves Type [Axis]
Valuation Allowances and Reserves [Domain]
Valuation Allowances and Reserves [Domain]
Valuation Allowance, Tax Credit Carryforward [Member]
Valuation Allowance, Tax Credit Carryforward [Member]
Valuation Allowance, Operating Loss Carryforwards [Member]
Valuation Allowance, Operating Loss Carryforwards [Member]
Income Tax Authority [Axis]
Income Tax Authority [Axis]
Income Tax Authority [Domain]
Income Tax Authority [Domain]
Federal [Member]
Domestic Tax Authority [Member]
State [Member]
State and Local Jurisdiction [Member]
Foreign [Member]
Foreign Tax Authority [Member]
Puerto Rico Excise Tax [Member]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward, Name [Domain]
Tax Credit Carryforward, Name [Domain]
Research Tax Credit Carryforward [Member]
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes
Tax Credit Carryforward, Amount
NOL carryforwards available to reduce income taxes
Operating Loss Carryforwards
Decrease in unrecognized tax benefits that is reasonably possible within the succeeding twelve months due to potential tax settlements
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit
Undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States
Undistributed Earnings of Foreign Operations On Which Domestic Income Tax Not Provided
Undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States.
Additional income taxes required to be accrued and paid if earnings of foreign operations that are intended to be indefinitely invested outside of the United States were repatriated
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries
Tax benefit of the retroactive extension of the 2012 R&D tax credit
Tax Benefits Recognized from Recently Enacted Legislation
Tax Benefits Recognized from Recently Enacted Legislation
Excise Tax Rate [Abstract]
Excise Tax Rate [Abstract]
Excise Tax Rate [Abstract]
Effective excise tax rate for 2012
Excise Tax Rate For Two Thousand Twelve
Excise tax rate for 2012.
Effective excise tax rate for first half of 2013
Excise Tax Rate For Two Thousand Thirteen
Excise tax rate for 2013.
Excise tax rate effective July 1, 2013 through 2017
Excise Tax, Percent
Excise Tax, Percent
Payables and Accruals [Abstract]
Accrued liabilities
Schedule of Accrued Liabilities [Table Text Block]
Restructuring and other cost savings initiatives
Restructuring and Related Activities Disclosure [Text Block]
Statement of Stockholders' Equity [Abstract]
Statement [Table]
Statement [Table]
Number of shares of common stock [Member]
Common Stock [Member]
Common stock and additional paid-in capital [Member]
Common Stock Including Additional Paid in Capital [Member]
Accumulated deficit [Member]
Retained Earnings [Member]
Accumulated other comprehensive income (loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance, Shares
Common Stock, Shares, Outstanding
Beginning Balance
Stockholders' Equity Attributable to Parent
Other comprehensive income (loss), net of tax
Other Comprehensive Income (Loss), Net of Tax
Dividends
Dividends, Common Stock, Cash
Issuance of common stock in connection with the Company’s equity award programs, Shares
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures
Issuance of common stock in connection with the Company’s equity award programs
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures
Stock-based compensation
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition
Settlement of conversion value of convertible debt in excess of principal
Adjustments to Additional Paid in Capital, Settlement of Conversion Value of Convertible Debt in Excess of Principal
Adjustments to Additional Paid in Capital, Settlement of Conversion Value of Convertible Debt in Excess of Principal
Settlement of convertible note hedge
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Settlement of warrants
Adjustments to Additional Paid in Capital, Settlement of Warrants
Adjustments to Additional Paid in Capital, Settlement of Warrants
Tax impact related to employee stock-based compensation
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
Repurchases of common stock, Shares
Repurchases of common stock
Stock Repurchased and Retired During Period, Value
Ending Balance, Shares
Ending Balance
Statement of Comprehensive Income [Abstract]
Other comprehensive income (loss), net of reclassification adjustments and taxes:
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Foreign currency translation losses
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent
Effective portion of cash flow hedges
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent
Net unrealized gains (losses) on available-for-sale securities
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
Other
Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent
Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent
Other comprehensive income (loss), net of tax
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Comprehensive income
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Maturities of Long-term Debt [Abstract]
Maturities of Long-term Debt [Abstract]
2015
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months
2016
Long-term Debt, Maturities, Repayments of Principal in Year Two
2017
Long-term Debt, Maturities, Repayments of Principal in Year Three
2018
Long-term Debt, Maturities, Repayments of Principal in Year Four
2019
Long-term Debt, Maturities, Repayments of Principal in Year Five
Thereafter
Long-term Debt, Maturities, Repayments of Principal after Year Five
Total
Long Term Debt Maturities Repayments Of Principal Net
Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.
Fair Value Hedging [Member]
Fair Value Hedging [Member]
Other notes [Member]
Other notes [Member]
Other notes [Member]
Convertible Notes Payable [Member]
Convertible Notes Payable [Member]
Commercial Paper [Member]
Commercial Paper [Member]
Line of Credit [Member]
Line of Credit [Member]
Medium-term Notes [Member]
Medium-term Notes [Member]
Floating Rate Notes Due 2017 [Member]
.375% Convertible Notes Due 2013 [Member]
Point Three Seven Five Percent Convertible Notes Due 2013 [Member]
Point Three Seven Five Percent Convertible Notes Due 2013 [Member]
Notes due in 2097 [Member]
Notes Due in 2097 [Member]
Notes Due in 2097 [Member]
MN [Member]
MN [Member]
MN [Member]
Class of Stock [Axis]
Class of Stock [Axis]
Class of Stock [Domain]
Class of Stock [Domain]
Preferred Class A [Member]
Preferred Class A [Member]
Debt Conversion Feature [Axis]
Debt Conversion Feature [Axis]
Debt Conversion Feature [Axis]
Debt Conversion Feature [Domain]
Debt Conversion Feature [Domain]
[Domain] for Debt Conversion Feature [Axis]
Excess Conversion Value [Member]
Excess Conversion Value [Member]
Excess Conversion Value [Member]
Shelf Registration Statement [Axis] [Axis]
Shelf Registration Statement [Axis] [Axis]
Shelf Registration Statement [Axis] [Axis]
Shelf Registration Statement [Axis] [Domain]
Shelf Registration Statement [Axis] [Domain]
[Domain] for Shelf Registration Statement [Axis] [Axis]
Shelf Registration Statement [Member]
Shelf Registration Statement [Member]
Shelf Registration Statement [Member]
Financing arrangements (Textual) [Abstract]
Financing Arrangements (Textual) [Abstract]
Financing arrangements.
Repayments of notes payable
Repayments of Notes Payable
Repayments of other debt
Repayments of Other Long-term Debt
Repayments of convertible notes
Repayments of Convertible Debt
Aggregate principal amount of notes issued
Debt Instrument, Face Amount
Basis spread on variable rate
Debt Instrument, Basis Spread on Variable Rate
Total debt issuance costs
Payments of Debt Issuance Costs
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event
Percentage Of Principal Amount Of Notes That May Be Paid Upon Occurrence Of Change In Control Triggering Event
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event.
Sale of stock, number of shares issued in transaction
Sale of Stock, Number of Shares Issued in Transaction
Description of variable rate basis
Debt Instrument, Description of Variable Rate Basis
Debt instrument, periodic payment, principal
Debt Instrument, Periodic Payment, Principal
Cash settlement of convertible bond hedge
Derivative, Cash Received on Hedge
Class of warrant or right, number of securities called by warrants or rights
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Exercise price of warrants
Class of Warrant or Right, Exercise Price of Warrants or Rights
Payments for repurchase of warrants
Payments for Repurchase of Warrants
Effective interest rate
Debt Instrument, Interest Rate, Effective Percentage
Non-cash interest expense
Non Cash Interest Expense
Non Cash Interest Expense on our convertible notes
Carrying amount of equity component of debt
Debt Instrument, Convertible, Carrying Amount of Equity Component
Interest rate swap contracts - fair value hedge - notional amounts
Maximum borrowing capacity under commercial paper program
Maximum Borrowing Capacity Under Commercial Paper
Maximum Borrowing Capacity Under Commercial Paper Program.
Amount outstanding under commercial paper program
Commercial Paper
Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement
Line of Credit Facility, Maximum Borrowing Capacity
Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks
Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks
Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.
Initial commitment term of each bank which is a party to the agreement
Line of Credit Facility, Initial Commitment Term
Line of Credit Facility, Initial Commitment Term
Number of additional extensions
Line of Credit Facility, Number of Extensions
Line of Credit Facility, Number of Extensions
Additional period for extension of commitment term
Line of Credit Facility, Extension of Commitment Term
Line of Credit Facility, Extension of Commitment Term
Annual commitment fees for syndicated, unsecured, revolving credit agreement
Line of Credit Facility, Commitment Fee Percentage
Amount outstanding under syndicated, unsecured, revolving credit facility
Long-term Line of Credit
Amount that may be issued under a medium term note program established under the shelf registration statement
Amount That May Be Issued Under Medium Term Note Program Established Under Shelf Registration Statement
Amount that may be issued under medium term note program established under the shelf registration statement.
Amount outstanding under medium term note program
Medium-term Notes
Interest costs capitalized
Interest Costs Capitalized
Interest paid, net of interest rate swaps
Interest Paid
Schedule of Property, Plant and Equipment [Table]
Property, Plant and Equipment [Table]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Domain]
Property, Plant and Equipment, Type [Domain]
Building and Improvements [Member]
Building and Building Improvements [Member]
Manufacturing Equipment [Member]
Manufacturing Equipment [Member]
Manufacturing equipment.
Laboratory Equipment [Member]
Laboratory Equipment [Member]
Laboratory equipment.
Other [Member]
Property, Plant and Equipment, Other Types [Member]
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Minimum [Member]
Minimum [Member]
Maximum [Member]
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment [Line Items]
Useful life
Property, Plant and Equipment, Useful Life
Property, plant and equipment [Abstract]
Property Plant and Equipment Excluding Depreciation And Amortization Charges [Abstract]
Property plant and equipment excluding depreciation and amortization charges.
Land
Land
Buildings and improvements
Buildings and Improvements, Gross
Manufacturing equipment
Machinery and Equipment, Gross
Laboratory equipment
Laboratory Equipment
Carrying amount as of the balance sheet date of laboratory equipment, gross.
Other
Property, Plant and Equipment, Other, Gross
Construction in progress
Construction in Progress, Gross
Property, plant and equipment, gross
Property, Plant and Equipment, Gross
Less accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Property, plant and equipment, net
Summary of significant accounting policies
Significant Accounting Policies [Text Block]
Accrued liabilities [Abstract]
Accrued Liabilities, Current [Abstract]
Sales deductions
Accrued Sales Deductions Current
Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.
Employee compensation and benefits
Employee-related Liabilities, Current
Clinical development costs
Accrued Liabilities, Clinical Development Costs
Accrued Liabilities, Clinical Development Costs
Dividends payable
Dividends Payable, Current
Sales returns reserve
Accrued Sales Return Reserve Current
Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.
Other
Other Accrued Liabilities, Current
Total accrued liabilities
Accrued Liabilities, Current
Takeda Pharmaceutical Company Limited [Member]
Collaborative Arrangements With Takeda Pharmaceutical Company Limited [Member]
Collaborative arrangements with Takeda pharmaceutical company limited.
Japanese Market Products [Member]
Japanese Market Products [Member]
Japanese market products.
Vectibix [Member]
Sale of Vectibix [Member]
Sale of Vectibix.
Number of molecules developed and commercialized as per collaborations
Number Of Molecules Developed And Commercialized As Per Collaborations
Number of molecules developed and commercialized as per collaborations.
Deferred revenue as of the date of modification of the original arrangement
Deferred Revenue, Revenue Recognized
Royalties received on sales
Royalties Received On sales
Royalties received on sales.
Goodwill [Roll Forward]
Goodwill [Roll Forward]
Beginning balance
Goodwill related to acquisitions of businesses
Goodwill, Acquired During Period
Currency translation and other adjustments
Goodwill, Other Changes
Ending balance
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year
Unrecognized Tax Benefits
Additions based on tax positions related to the current year
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Additions based on tax positions related to prior years
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions
Reductions for tax positions of prior years
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Reductions for expiration of statute of limitations
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Settlements
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
Balance at end of year
Provision for income taxes
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Significant components of deferred tax assets and liabilities
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)
Reconciliation of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns [Table Text Block]
Tabular disclosure showing reconciliation of total gross amounts of unrecognized tax benefits.
Reconciliation between the federal statutory tax rate and effective tax rate
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Depreciation and amortization charges associated with property, plant and equipment
Depreciation
Astrazeneca Plc. [Member]
Collaborative Arrangements With Astrazeneca Plc [Member]
Collaborative arrangement with AstraZeneca PLC.
Percentage of related development costs for the 2012-2014 period that were funded by partner
Percentage Of Related Development Costs
Percentage of related development costs to be funded by partner.
Milestone payments received
Commercial Milestones Received Under Collaborative Arrangements
Commercial milestones received under collaborative arrangements.
Schedule of notional amounts and interest rates for cross-currency swaps
Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]
Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]
Location in the Consolidated Statements of Income and the effective portion of gain (loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges
Statements Of Income And Effective Portion Of Gain Loss Reclassified From Accumulated Other Comprehensive Income Into Income For Our Cash Flow Hedge Contracts [Table Text Block]
Tabular disclosure of the location in the Consolidated Statements of Income and the effective portion of the gain (loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges.
Location in the Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for the derivative instruments not designated as hedging instruments
Statements Of Income And Amount Of Gain Recognized In Income For Derivative Instruments Not Designated As Hedging Instruments [Table Text Block]
Tabular disclosure of the location in the Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for the derivative instruments not designated as hedging instruments.
Fair values of derivatives included in the Consolidated Balance Sheets
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]
Accrued liabilities
Accrued Liabilities Disclosure [Text Block]
Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.
Bayer HealthCare Pharmaceuticals Inc. [Member]
Collaborative Arrangements with Bayer HealthCare Pharmaceuticals Inc. [Member]
Collaborative Arrangements with Bayer HealthCare Pharmaceuticals Inc. [Member]
Nexavar [Member]
Nexavar [Member]
Nexavar [Member]
Number of countries product is marketed and sold
Number of Countries Product is Marketed and Sold
Number of Countries Product is Marketed and Sold
Percentage of development costs funded by Company
Percentage of Development Costs Funded by Company
Percentage of Development Costs Funded by Company
Percentage of net profits after deducting certain partner related costs
Percentage of Net Profits After Deducting Certain Partner Related Costs
Percentage of Net Profits After Deducting Certain Partner Related Costs
Collaboration profit
Collaborative Arrangement, Net Income
Collaborative Arrangement, Net Income
Collaboration, net R&D expenses
Collaborative Arrangement, Research and Development Expense, Net
Collaborative Arrangement, Research and Development Expense, Net
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Available-for-sale Securities [Table Text Block]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]
Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.
Fair values of available-for-sale interest-bearing security investments by contractual maturity
Investments Classified by Contractual Maturity Date [Table Text Block]
Available-for-sale securities, continuous unrealized loss position, fair value
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Entity Central Index Key
Document Type
Document Type
Document Period End Date
Document Period End Date
Amendment Flag
Amendment Flag
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Voluntary Filers
Entity Current Reporting Status
Entity Current Reporting Status
Entity Filer Category
Entity Filer Category
Entity Public Float
Entity Public Float
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Beginning balance
Additions from Onyx acquisition
Business Combination, Contingent Consideration Arrangements, Addition from Acquisitions
Business Combination, Contingent Consideration Arrangements, Addition from Acquisitions
Net changes in valuation
Settlement of contingent consideration
Ending balance
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)
Common Stock, Par or Stated Value Per Share
Common stock and additional paid-in capital, shares authorized
Common Stock, Shares Authorized
Common stock and additional paid-in capital, shares outstanding
Gross profit from product sales
Gross Profit
Earnings per share:
ASSETS
Assets [Abstract]
Current assets:
Assets, Current [Abstract]
Trade receivables, net
Accounts Receivable, Net, Current
Inventories
Other current assets
Other Assets, Current
Total current assets
Assets, Current
Property, plant and equipment, net
Intangible assets, net
Goodwill
Other assets
Total assets
Assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities and Equity [Abstract]
Current liabilities:
Liabilities, Current [Abstract]
Accounts payable
Accounts Payable, Current
Accrued liabilities
Current portion of long-term debt
Total current liabilities
Liabilities, Current
Long-term debt
Long-term deferred tax liability
Deferred Tax Liabilities, Net, Noncurrent
Other noncurrent liabilities
Other Liabilities, Noncurrent
Contingencies and commitments
Commitments and Contingencies
Stockholders’ equity:
Stockholders' Equity Attributable to Parent [Abstract]
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 760.4 shares in 2014 and 754.6 shares in 2013
Common Stocks, Including Additional Paid in Capital
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Accumulated other comprehensive loss
Total stockholders’ equity
Total liabilities and stockholders’ equity
Liabilities and Equity
Inventories
Inventory Disclosure [Text Block]
Collaborative arrangements
Collaborative Arrangement Disclosure [Text Block]
Financing arrangements
Debt Disclosure [Text Block]
Glaxo Group Limited [Member]
Collaborative Arrangement With Glaxo Group Limited [Member]
Collaborative Arrangement with Glaxo Group Limited.
deCODE Genetics [Member]
Mustafa Nevzat Pharmaceuticals [Member]
Micromet Inc. [Member]
Equity Award Holders [Axis]
Equity Award Holders [Axis]
Equity Award Holders [Axis]
Equity Award Holders [Domain]
Equity Award Holders [Domain]
[Domain] for Equity Award Holders [Axis]
Common Stockholders [Member]
Common Stockholders [Member]
Common Stockholders [Member]
Equity Award Holders for Services Rendered Prior to Date of Acquisition [Member]
Equity Award Holders for Services Rendered Prior to Date of Acquisition [Member]
Equity Award Holders for Services Rendered Prior to Date of Acquisition [Member]
In Process Research and Development [Member]
Other operating expense [Member]
Other Operating Income (Expense) [Member]
Scenario [Axis]
Scenario, Unspecified [Domain]
Pro Forma [Member]
Pro Forma [Member]
Number of partnered oncology assets
Number of Partnered Oncology Assets
Number of Partnered Oncology Assets
Cash payments
Payments to Acquire Businesses, Gross
Share-based compensation expense
Allocated Share-based Compensation Expense
Reduction in goodwill
Goodwill, Purchase Accounting Adjustments
Increase in developed product technology rights
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles
Increase in deferred income taxes
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes
Decrease in inventory
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory
Finite-lived intangible assets, estimated useful life (in years)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life
Number of separate milestone payments
Contingent consideration obligations
Transaction related expenses
Business Combination, Acquisition Related Costs
Intangible asset amortization expense
Number of markets holding acquired licenses
Number of Markets Holding Acquired Licenses
Number of Markets Holding Acquired Licenses
Settlement of preexisting relationship at fair value
ComponentOfOtherOperatingCostAndExpenseGeneralAxis [Axis]
ComponentOfOtherOperatingCostAndExpenseGeneralAxis [Axis]
ComponentOfOtherOperatingCostAndExpenseGeneralAxis [Axis]
ComponentOfOtherOperatingCostAndExpenseGeneralAxis [Domain]
ComponentOfOtherOperatingCostAndExpenseGeneralAxis [Domain]
[Domain] for ComponentOfOtherOperatingCostAndExpenseGeneralAxis [Axis]
Other operating expense [Member]
OtherOperatingExpenseMember [Member]
OtherOperatingExpenseMember [Member]
Manufacturing operations optimization [Member]
Manufacturing Operations Optimization [Member]
Manufacturing operations optimization.
Other cost savings initiative [Member]
Other Cost Savings Initiative [Member]
Other cost savings initiative.
Expected number of positions eliminated
Restructuring and Related Cost, Expected Number of Positions Eliminated
Restructuring expected cost
Restructuring and Related Cost, Expected Cost
Restructuring expected separation cost
Restructuring and Related Cost, Expected Cost, Separation Costs
Restructuring and Related Cost, Expected Cost, Separation Costs
Restructuring expected asset impairments, accelerated depreciation and other related costs
Restructuring and Related Cost, Expected Cost, Accelerated Depreciation and Asset Impairment Charges and Other Costs
Restructuring and Related Cost, Expected Cost, Accelerated Depreciation and Asset Impairment Charges and Other Costs
Restructuring costs and asset impairment charges
Impairment of fixed assets to be disposed of
Impairment of Long-Lived Assets to be Disposed of
Severance and lease termination costs
Charges Primarily Related to Severance and Exiting Leased Facilities
Charges against earnings in the period for costs associated with terminating operating leases and severance costs.
Total consideration transferred
Compensation expense
Business Combination, Payments of Accelerated Vesting Equity Awards
Business Combination, Payments of Accelerated Vesting Equity Awards
Total cash paid
Payments to Acquire Businesses and Accelerated Equity Awards
Payments to Acquire Businesses and Accelerated Equity Awards
Summary of restructuring charges by type of activity
Restructuring and Related Costs [Table Text Block]
Restructuring liabilities roll forward
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]